Literature DB >> 1863521

Clinical application of indium-111 antimyosin antibody and thallium-201 dual nuclide single photon emission computed tomography in acute myocardial infarction.

H Yoshida1, M Mochizuki, M Kainouchi, T Ishida, K Sakata, S Yokoyama, T Hoshino, M Takezawa, Y Matsumoto, T Miyamoto.   

Abstract

The significance of indium-111 antimyosin antibody and thallium-201 dual nuclide single photon emission computed tomography (SPECT) was evaluated in 7 patients with acute myocardial infarction (AMI) who underwent emergency coronary angiography with successful revascularization by intracoronary thrombolysis. Indium-111 antimyosin antibody and thallium-201 dual nuclide SPECT was performed 11 to 36 days after the onset of AMI. Antimyosin SPECT images delineated areas of myocardial necrosis in all 7 patients (100%), but planar images detected necrotic areas in only 4 of 7 patients (57%). Peak CPK-MBs of the 3 patients in which no necrotic area was detected by indium-111 planar image showed a tendency to be smaller. Indium-111 antimyosin antibody/thallium-201 overlap was observed in all patients. The area of overlap was at the center of necrosis in 4 patients (2 anterior infarction, 1 inferior infarction, 1 inferolateral infarction) and at the peripheral portion in 3 patients (all 3 had inferior infarction). Indium-111 antimyosin antibody and thallium-201 dual nuclide SPECT is useful in identifying the localization of myocardial infarction and the overlap of these tracers might reflect the presence of salvaged myocardium adjacent to the necrotic myocardium.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1863521     DOI: 10.1007/bf03164612

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  14 in total

1.  The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs.

Authors:  K A Reimer; J E Lowe; M M Rasmussen; R B Jennings
Journal:  Circulation       Date:  1977-11       Impact factor: 29.690

2.  Clinical significance of early myocardial 99mTc-pyrophosphate uptake in patients with acute myocardial infarction.

Authors:  M Kondo; M Takahashi; T Matsuda; N Kume; Y Yuzuki; Y Shimono; H Fujiwara
Journal:  Am Heart J       Date:  1987-02       Impact factor: 4.749

3.  Thallium-201/technetium-99m pyrophosphate overlap in patients with acute myocardial infarction after thrombolysis: prediction of depressed wall motion despite thallium uptake.

Authors:  J Schofer; R P Spielmann; T Brömel; W Bleifeld; D G Mathey
Journal:  Am Heart J       Date:  1986-08       Impact factor: 4.749

Review 4.  The role of antimyosin antibodies in acute myocardial infarction.

Authors:  L L Johnson; D W Seldin
Journal:  Semin Nucl Med       Date:  1989-07       Impact factor: 4.446

5.  Dual isotope thallium and indium antimyosin SPECT imaging to identify acute infarct patients at further ischemic risk.

Authors:  L L Johnson; D W Seldin; A M Keller; R M Wall; K Bhatia; C O Bingham; M E Tresgallo
Journal:  Circulation       Date:  1990-01       Impact factor: 29.690

6.  Localization of radiolabeled cardiac myosin-specific antibody in myocardial infarcts. Comparison with technetium-99m stannous pyrophosphate.

Authors:  G A Beller; B A Khaw; E Haber; T W Smith
Journal:  Circulation       Date:  1977-01       Impact factor: 29.690

7.  Myocardial injury: quantitation by cell sorting initiated with antimyosin fluorescent spheres.

Authors:  B A Khaw; J Scott; J T Fallon; S L Cahill; E Haber; C Homcy
Journal:  Science       Date:  1982-09-10       Impact factor: 47.728

8.  Acute myocardial infarct extension into a previously preserved subendocardial region at risk in dogs and patients.

Authors:  R Forman; S Cho; S M Factor; E S Kirk
Journal:  Circulation       Date:  1983-01       Impact factor: 29.690

9.  Antimyosin imaging in acute transmural myocardial infarctions: results of a multicenter clinical trial.

Authors:  L L Johnson; D W Seldin; L C Becker; N D LaFrance; H A Liberman; C James; J A Mattis; R T Dean; J Brown; A Reiter
Journal:  J Am Coll Cardiol       Date:  1989-01       Impact factor: 24.094

10.  Measurement of infarct size and percentage myocardium infarcted in a dog preparation with single photon-emission computed tomography, thallium-201, and indium 111-monoclonal antimyosin Fab.

Authors:  L L Johnson; K S Lerrick; J Coromilas; D W Seldin; P D Esser; J M Zimmerman; A M Keller; P O Alderson; J T Bigger; P J Cannon
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

View more
  2 in total

1.  Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy.

Authors:  Wiebke Sihver; Jens Pietzsch; Mechthild Krause; Michael Baumann; Jörg Steinbach; Hans-Jürgen Pietzsch
Journal:  Pharmaceuticals (Basel)       Date:  2014-03-05

2.  Radiolabeled F(ab')2-cetuximab for theranostic purposes in colorectal and skin tumor-bearing mice models.

Authors:  P-S Bellaye; M Moreau; O Raguin; A Oudot; C Bernhard; J-M Vrigneaud; L Dumont; D Vandroux; F Denat; A Cochet; F Brunotte; B Collin
Journal:  Clin Transl Oncol       Date:  2018-05-17       Impact factor: 3.405

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.